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Adenoviruses (Ads) cause fatal disease in allogeneic stem cell transplant recipients, but there is no established therapy. Ad-specific CD8+ T
cells were detected in PBMC from healthy adults at a mean frequency of 77 per 105 CD8+ T cells (range 8–260) by interferon-γ ELISPOT and
cytokine flow cytometry assays. CD8+ T cell lines from 7 of 7 donors exhibited MHC-class-I-restricted killing of targets expressing the capsid
protein hexon. In contrast, cytotoxicity against the capsid proteins fiber and penton base was weaker or not detected. Two HLA-A2-restricted
hexon epitopes and one HLA-B-restricted epitope were identified, all of which are adjacent to or overlap an HLA-DP4-restricted epitope in the
highly conserved C-terminus. Thus, hexon is the immunodominant T cell target among capsid proteins and contains multiple C-terminal epitopes
conserved among serotypes. These data support evaluation of donor lymphocyte infusions for treatment of Ad disease post-transplant.
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Adenoviruses (Ads) are uncommon but potentially fatal
opportunistic pathogens in severely immunocompromised
patients such as hematopoietic stem cell transplant (SCT)
recipients (Flomenberg et al., 1994; Kojaoghlanian et al., 2003).
The group C Ad types 1, 2, and 5 and the distantly related group
B Ad types 11, 34, and 35 are most commonly associated with
Ad disease post-SCT, but infections with most other serotypes
have been described. There is no established therapy, although
treatment with cidofovir, a broad spectrum antiviral agent with
modest in vitro activity against Ads, has been associated with
clinical improvement in some cases (Legrand et al., 2001;
Ljungman et al., 2003). The mortality risk due to Ad disease
post-SCT is associated with absolute lymphocyte counts b300,
suggesting that recipients who develop a cellular immune
response may recover from Ad disease (Chakrabarti et al.,⁎ Corresponding author. Department of Medicine, Thomas Jefferson Univer-
sity, 1020 Locust St., Room 329, Philadelphia, PA 19107, USA. Fax: +1 215
923 1956.
E-mail address: phyllis.flomenberg@mail.tju.edu (P. Flomenberg).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.01.0242002). Therefore, T cell immunotherapy may be of benefit,
especially in SCT recipients of T-cell-depleted grafts who have
severe and prolonged lymphopenia.
Most individuals have been exposed to Ads and have Ad-
specific antibodies, but little is known about Ad-specific T cell
responses. Ads are non-enveloped viruses that have an outer
protein capsid consisting of the proteins hexon, penton base
(penton), and fiber, all of which contain unique antigenic
determinants that define over 50 different serotypes (Kojaogh-
lanian et al., 2003). Hexon represents the dominant capsid
protein quantitatively and contains several regions that are
conserved among different serotypes (Rux et al., 2003). This
laboratory previously detected memory Ad-specific CD4+ Tcell
responses in peripheral blood mononuclear cells (PBMC) from a
majority of healthy adults (Flomenberg et al., 1995; Olive et al.,
2001). A CD4+ T cell epitope from the C-terminus of the major
capsid protein hexon, H910–924, was identified that was highly
conserved among different Ad serotypes (Olive et al., 2002).
This epitope is restricted byHLADP4, the most common class II
allele, and is recognized by 75% of healthy adults (Tang et al.,
2004). Additionally, memory Ad-specific CD8+ Tcell responses
were detected against Ad-infected autologous fibroblasts
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shown that Ad-specific cytotoxic T cells (CTLs) recognize
different Ad serotypes (Leen et al., 2004a; Smith et al., 1998).
Recently, their group has identified and characterized several
CD8+ T cell clones that recognize hexon (Leen et al., 2004b).
The goal of this study was to compare memory CD8+ CTL
responses to the Ad capsid proteins hexon, penton, and fiber in
healthy adults. Autologous dendritic cells (DC) were utilized to
present input Ad capsid proteins in vitro. Although Ad
replication is restricted in hematopoietic cells, including DC,
Ads can bind and enter at high multiplicity of infection (Leon et
al., 1998). DC are professional antigen-presenting cells that are
capable of efficiently processing input proteins via both class I
and class II antigens (Albert et al., 1998; Larsson et al., 2003).
Ad-infected DC were employed as stimulators to directly assay
PBMC for Ad-specific CD8+ T cell responses using short-termFig. 1. Detection of Ad-specific memory CD4+ and CD8+ T cells from PBMC. Perip
stimulated with Ad5-infected or uninfected autologous dendritic cells (DC) (PBM
measured by cytokine flow cytometry using 4-color staining. CD4+ T cells were
lymphocytes. Ad-specific precursor frequencies were calculated by subtracting the rIFN-γ ELISPOT and cytokine flow cytometry (CFC) assays
and to prepare Ad-specific T cell lines (TCL). Ad-specific CD8+
T cell cytotoxic responses to hexon, penton, and fiber were
identified using recombinant vaccinia vectors (Vac) to express
individual Ad capsid proteins in target cells. Additionally,
hexon-specific CD8+ T cell epitopes were localized with hexon
truncation mutants and synthetic peptides.
Results
Ad-specific CD8+ T cells are present at low frequencies in
PBMC from healthy adults
PBMC from donors 1 and 2 were stimulated with Ad-infected
autologousDC for 6 h and assayed for intracellular IFN-γ expression
by the CFC assay. PBMC were incubated with uninfected DC as aheral blood mononuclear cells (PBMC) from donor 1 (A) and donor 2 (B) were
C:DC ratio 30:1) for 6 h, and activated IFN-γ and CD69-positive cells were
gated on CD3+/CD8− lymphocytes. CD8+ T cells were gated on CD3+/CD8+
esponses to uninfected DC (see text).
Fig. 2. Ad-specific CD8+ CTL recognize epitopes conserved between Ad5 and
Ad35. Purified CD8+ T cells were stimulated with Ad5-infected autologous
dendritic cells (DC) for 1–3 weeks and assayed for responses to Ad5- or Ad35-
infected DC, uninfected DC, or 1 μM HLA-DP4-restricted hexon peptide
H910–924 by IFN-γ ELISPOT assay. Ad-specific responses were calculated by
subtracting the responses to uninfected DC (see text). SFCs, spot-forming cells.
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detected in 0.26% of CD8+ Tcells and 0.15% of CD4+ Tcells from
donor 1. In contrast, only 0.02% of CD8+ T cells from donor 2
responded to Ad-infected DC, compared to 0.62% of CD4+ T cells.
These data suggested that there was a wide range in Ad-specific
CD8+ T cell precursor frequencies among donors.
To more precisely measure low frequencies of Ad-specific
CD8+ T cells in PBMC, the IFN-γ ELISPOT assay was
employed. Since the IFN-γ ELISPOT assay does not distin-
guish between CD4+ and CD8+ T cell responses, CD8+ T cells
were purified from PBMC from 4 donors (3, 4, 5, and 6) by
immunomagnetic selection. Both purified CD8+ T cells and
whole PBMC were incubated with Ad5-infected and uninfected
autologous DC. As controls, the CD4+ T-cell-specific UV-
inactivated Ad antigen and the HLA-DP4-restricted peptide
H910–924 were tested. A summary of the results from all 6
donors is shown in Table 1. Whole PBMC from all 4 donors
exhibited specific IFN-γ responses to Ad-infected DC,
inactivated Ad antigen, and H910–924 (except HLA DP4
negative donor 6 does not respond to H910–924). In contrast,
purified CD8+ T cells responded only to Ad-infected DC (data
not shown). The percentage of Ad-specific CD8+ T cell
responders compared to whole PBMC responders varied from
0.9 to 30.2%, consistent with relatively higher frequencies of
Ad-specific CD4+ T cells. Ad-specific CD8+ memory T cells
were detected in peripheral blood at a mean frequency of 77 per
105 CD8+ T cells (range 8–260).
Stimulation of purified CD8+ T cells with Ad5-infected DC
amplifies CD8+ CTL that recognize Ad35
Purified CD8+ T cells from PBMC from 7 donors (3, 4, 5, 6,
7, 8, and 9) were stimulated with Ad5-infected autologous DC
for 2 weeks, as described under Materials and methods. All
CD8+ CTL exhibited specific cytotoxicity against Ad-infected
autologous DC. Weekly analyses of the CD8+ CTL by IFN-γ
ELISPOT assay revealed amplification of specific IFN-γ
responses to Ad-infected DC and lack of response to the HLA-
DP4-restricted peptide H910–924, consistent with the absenceTable 1
Comparison of frequencies of virus-specific memory CD8+ T cell responses to
Ad5-infected dendritic cells among healthy adults a
Donor No. of responders/106
whole PBMC
No. of responders/
105 CD8+ T cells
CD8+ responders/total
responders b (%)
1c 860 260 30.2
2c 2225 20 0.9
3 1600 25 1.6
4 180 8 4.6
5 668 41 6.1
6 636 107 16.8
a Peripheral blood mononuclear cells (PBMC) and purified CD8+ T cells were
stimulated 20 h with either Ad5-infected or uninfected dendritic cells and
assayed by IFN-γ ELISPOT. No. of responders = no. of spot-forming cells in
experimental - control wells.
b CD8 T cells were estimated to represent 10% of total PBMC.
c Donor 1 and 2 PBMC were assayed for IFN-γ responses to Ad5-infected
dendritic cells by cytokine flow cytometry.of Ad-specific CD4+ T cells (Fig. 2). Additionally, CD8+ CTL
recognized DC infected with the group B Ad35; the mean Ad35
response was 45% of the response to Ad5-infected DC.
All Ad-specific CD8+ CTL exhibit class-I-restricted killing of
hexon; fiber and penton responses were less consistent
Ad-specific CD8+ CTL from 7 of 7 donors exhibited specific
killing of autologous Epstein–Barr virus (EBV)-transformed
lymphoblastoid cell line (LCL) targets expressing hexon from a
recombinant Vac vector (data not shown). In comparison, more
modest killing of targets infected with either Vac/penton or Vac/
fiber was detected, and responses varied among the 5 donors
tested. Representative CTL assays are presented in Fig. 3. One
CTL line (donor 4) exhibited moderate cytotoxicity against
targets expressing penton but did not kill fiber-expressing
targets (Fig. 3A). Three CTL lines (donors 3, 5, and 7) exhibited
moderate cytotoxicity against both penton- and fiber-expressing
targets, as illustrated in Fig. 3B. In contrast, one CTL line
(donor 6) did not kill targets expressing either penton or fiber
(Fig. 3C). Hexon-specific cytotoxicity was MHC-restricted and
specifically blocked by an mAb against HLA class I antigens in
all donors (data not shown). Additionally, CD8+ CTLs from
HLA A2-positive donor 3 exhibited HLA A2-specific cyto-
toxicity (Figs. 4A and B).
Ad-specific CD8+ T cells recognize hexon N-terminal and
distal C-terminal epitopes
In order to help identify CD8+ T cell epitopes, a panel of
hexon truncation mutants was expressed from Vac vectors in
targets and tested against the Ad-specific CD8+ CTLs.
Fig. 3. Comparison of Ad-specific CD8+ CTL responses to the capsid proteins hexon, penton, and fiber among donors. Purified CD8+ T cells were stimulated with
Ad5-infected autologous dendritic cells for 2–3 weeks. Cytotoxicity against autologous EBV-transformed lymphoblastoid cell line targets infected overnight with
vaccinia vectors expressing hexon, penton, fiber, or influenza matrix protein (control) was measured by calcein release assay. Three different response patterns are
illustrated in panels A (donor 4), B (donor 7), and C (donor 6). E:T ratio, effector/target ratio.
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insertion of stop codons located at a.a. positions 437, 639, and
859 in the Ad5 hexon ORF (951 a.a.), as described under
Materials and methods. Expression of appropriate sized mutant
hexon proteins was confirmed by Western blot analysis of cells
infected with Vac/Ad mutant hexon containing truncations at
639 and 859 a.a., using both a rabbit antibody raised against
purified hexon and human sera (data not shown). Neither sera
detected expression of the smallest hexon mutant truncated at
a.a. position 437. Ad-specific CD8+ CTL from 3 donors were
tested for the ability to kill autologous LCL infected with each
Vac/Ad mutant hexon. Targets were infected either with Vac/
wild-type hexon or Vac/influenza matrix protein as positive
and negative controls, respectively.
Ad-specific CD8+ CTL from each donor recognized all 3
hexon truncation mutants, as shown in Fig. 5, but there were
significant differences among donors in the levels of cytotoxi-
city against each mutant. In the HLA A2-positive donor 7 (Fig.5A), there was N50% reduction in killing of all targets
expressing truncation mutants compared to wild-type hexon,
indicating that the major T cell response is targeted to the distal
C-terminus of hexon (a.a. positions 859–951) and a minor
response to the N-terminal half of hexon (1–436 a.a.s). In donor
4, there was a smaller but similar reduction of cytotoxicity
(b25%) against all targets expressing truncation mutants (Fig.
5B), suggesting the presence of a minor response to the distal C-
terminus and a major response to the N-terminal half of hexon.
In contrast, there was no significant difference in donor 6 CD8+
CTL responses against targets expressing truncated hexon
proteins and wild-type hexon (Fig. 5C), suggesting that this
donor primarily recognized epitopes in the N-terminal half of
hexon. Thus, CD8+ T cell responses were detected to both
regions 1–436 a.a.s (containing both variable and conserved
sequences) and the highly conserved distal C-terminal a.a.s
859–951. In contrast, no definite CD8+ T cell responses were
detected to the hexon region 437–858 a.a.s since there were no
Fig. 4. CD8+ CTLs exhibits HLA-A2-restricted killing of hexon. Purified CD8+
T cells from donor 3 (A2, A31; B13, B49; DR1, DR7; DQ2, DQ5; DP3, DP4)
were stimulated 2 weeks with Ad5-infected autologous (auto) dendritic cells,
and cytotoxicity was measured by calcein release assay against the following
targets. (A) Auto EBV-transformed lymphoblastoid cell line (LCL), HLA-A2-
matched only BM16 (A2, B18, DR12, DQ3, DP2), or HLA-DP4-matched only
MGAR (A26, B8, DR15, DQ3, DP4) infected overnight with vaccinia vectors
(Vac) expressing hexon or influenza matrix protein (control). (B) Vac/hexon-
infected auto LCL pre-incubated 1 h with 40 μg/ml mAb against HLA-ABC,
HLA-DR, or media alone. The E:T ratio (effector/target) was 40:1.
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positions 437, 639, or 859.
Identification of HLA-A2-restricted hexon epitopes in the
C-terminus
Ad-specific CD8+ CTLs from 3 HLA A2-positive donors (3,
7, and 9) were screened for responses to a panel of 18 HLA A2-
motif hexon peptides in the IFN-γ ELISPOT assay. The HLA-
A2-binding motif is very well defined and consists of specific
hydrophobic a.a.s (L, V, I, and M) at the primary anchor
positions 2 and 9; preferred and deleterious a.a.s have also been
identified at several other positions within the epitope (Parker et
al., 1994). HLA-A2-binding motifs were identified throughout
the Ad5 hexon sequence, 7 of which were previously described(Olive et al., 2002). IFN-γ responses from HLA A2-positive
CD8+ CTLs were detected to only two peptides, both of which
are located in the distal C-terminus. Peptide H892–901 was
recognized by donors 7 and 9 (not donor 3), whereas H916–925
was recognized by all three donors (data not shown). The
detection of responses to two C-terminal epitopes from donor 7
is consistent with the above truncation mutant analysis, which
demonstrated a major response to the distal C-terminus in this
donor.
Peptide-specific TCL were prepared for both H892–901 and
H916–925, as described under Materials and methods, and
tested for cytotoxicity. Representative assays are shown in Fig.
6. TCL specific for each peptide exhibited MHC-restricted
killing of hexon-expressing autologous LCL, confirming that
both peptides are naturally processed from hexon expressed in
cells (Fig. 6A). Hexon-specific killing was blocked by an mAb
against HLA class I antigens, but not anti-HLA DR, which
confirms that the cytotoxicity is class-I-restricted (Fig. 6B). The
fact that both TCL killed peptide-loaded HLA-A2-matched
only targets, but not HLA-mismatched targets, confirms the
HLA A2 restriction (Figs. 6C and D). Of note, peptide H916–
925 overlaps the previously described HLA-DP4-restricted
peptide H910–924 in the C-terminus (Tang et al., 2004). The
H892–901 epitope is also adjacent to the HLA-DP4-restricted
epitope H910–924 in the highly conserved C-terminus of
hexon.
Interestingly, the dominant CD8+ T cell response to hexon
from donor 3 (A2, A31; B13, B49) was directed towards a third
epitope, peptide H918–927. This peptide was tested as part of
an additional panel of peptides overlapping the HLA-DP4-
restricted epitope and does not contain a suitable HLA-A2-
binding motif. Donor 3 CD8+ CTL exhibited class-I-restricted
killing of hexon (Fig. 4). The CTL line had a 10-fold higher
response to H918–927 compared to H916–925 and did not
respond to H892–901 in the IFN-γ ELISPOT assay (Fig. 7A).
Cytotoxicity was detected to H918–927-loaded autologous
LCL but not targets matched for HLA A2 or HLA A31 (Fig.
7B). These data indicate that H918–927 is HLA-B-restricted
(HLA B13 or B49). The sequences of all 3 hexon CD8+ T cell
epitopes are highly conserved among different Ad serotypes
(Table 2).
Discussion
Ad-specific T cell responses are important for recovery
from Ad infections, but little is known about the target
proteins recognized. We previously identified the first Ad
CD4+ T cell epitope from the major capsid protein hexon C-
terminus, which is highly conserved among different serotypes
(Olive et al., 2002). This hexon epitope is restricted by HLA
DP4, the most common class II antigen in the general
population, and is recognized by 75% of healthy adults.
Rooney and colleagues recently identified several class-I-
restricted T cell epitopes from hexon (Leen et al., 2004b). We
now report on identification of memory Ad-specific CD8+
CTL responses to the individual hexon protein in PBMC from
7 of 7 healthy adults. Additionally, 3 new epitopes located in
Fig. 5. Comparison of CD8+ CTL responses to hexon truncation mutants. Purified CD8+ T cells were stimulated with Ad5-infected autologous dendritic cells for 2–3
weeks. Cytotoxicity was measured by calcein release assay against autologous EBV-transformed lymphoblastoid cell line targets infected overnight with vaccinia
vectors expressing either wild-type hexon, hexon truncated at a.a. positions 437, 639, or 859, or influenza matrix protein (control). Panel A (donor 7). Panel B (donor
4). Panel C (donor 6). E:T, effector/target ratio.
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contrast to the hexon response, CD8+ CTL responses to the
capsid proteins fiber and penton were weaker or not detectable
from all donors.
Ad-specific CD8+ T cell responses were directly identified in
PBMC by short-term stimulation with Ad-infected DC. DC,
professional antigen-presenting cells, were utilized in order to
efficiently process and present input Ad virion proteins via HLA
class I antigens. Ad-specific CD8+ T cells were detected from
all donors tested with a mean frequency of 77 per 105 CD8+ T
cells (range 8–260) by IFN-γ ELISPOT and cytokine flow
cytometry assays.
Stimulation of purified CD8+ T cells with Ad5-infected DC
allowed successful amplification of Ad-specific CD8+ CTL in
bulk culture. Ad5-specific CD8+ CTL recognized Ad35-infected DC, indicating that CD8+ T cells, like their CD4+
counterparts, recognize conserved epitopes between diverse
serotypes. As a control for the purity of the CD8+ CTL, no
responses were detected to the HLA-DP4-restricted peptide
(whole PBMC from all donors except HLA DP4-negative
donor 6 respond to H910–924). Ad-specific CD8+ CTL from
7 of 7 donors exhibited MHC-restricted cytotoxicity against
targets expressing hexon. Cytotoxicity was completely
blocked by mAb against HLA A, B, and C antigens in each
donor, confirming the class I restriction. Additionally, HLA-
A2-restricted killing of hexon-expressing targets was
documented.
Three hexon CD8+ T cell hexon epitopes were identified,
including 2 HLA-A2-restricted epitopes, all of which are
located in the highly conserved C-terminus. Notably, the HLA-
Fig. 6. CD8+ CTL recognize two HLA-A2-restricted epitopes in the hexon C-terminus. PBMC were stimulated 2 weeks with either synthetic peptide H892–901
(H892) or H916–925 (H916), and cytotoxicity was measured by calcein release assay. H892-specific T cells from donor 9 (A2, A31; B8, B38) were tested against the
following targets: (A) autologous EBV-transformed lymphoblastoid cell line targets (LCL) infected with Vac/hexon or Vac/influenza matrix protein (control); (B) Vac/
hexon-infected auto LCL pre-incubated 1 h with 40 μg/ml mAb against HLA-ABC, HLA-DR, or media alone (E:T ratio 40:1); and (C) HLA-A2-matched only Boleth
(A2, B75) and HLA-mismatched Mou (A29, B44) targets with or without peptide. In panel D, H916-specific T cells from donor 7 (A2, A3; B8, B51) were tested
against HLA-A2-matched only EJA2 (A2, A29; B14, B38) and HLA-mismatched Mou targets with or without peptide.
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epitope H918–927 directly overlap the HLA-DP4-restricted
epitope H910–924. The other HLA-A2-restricted epitope
H892–901 is adjacent to the HLA-DP4-restricted epitope.
Interestingly, one donor (A2, A31; B13, B49) exhibited a much
stronger response to the HLA-B-restricted peptide H918–927 in
comparison to the response to either HLA-A2-restricted
peptide. These data are consistent with the concept that the
specific combination of HLA types in an individual affects the
immunodominance of the CD8+ T cell response to a protein
(Lacey et al., 2003).
Additionally, analysis of hexon truncation mutants revealed
that CD8+ CTL from 3 of 3 donors recognize epitopes in the N-
terminal half of hexon (1–436 a.a.s), which contains both
variable and conserved sequences. Although the 437 a.a. hexon
mutant was not detected by Western blot analysis of cell lysates,
the positive CTL responses confirmed its expression in targets.
One explanation is that the smallest mutant hexon protein wasunstable and degraded within cells. Degradation of the mutant
hexon into fragments could prevent recognition of the protein
by polyclonal antibodies, but not CD8+ T cells which recognize
small peptides presented by class I antigens. Less likely, neither
polyclonal antibody recognizes the N-terminal half of hexon.
CTL responses to the hexon mutant 859 were lower than to
wild-type hexon, confirming the presence of epitopes in the
distal C-terminus in 2 of 3 donors. However, there was no clear
difference in responses to hexon mutants 437, 639, and 859 in
any of the donors, indicating that the region 437–858 a.a.s was
poorly recognized.
These data are consistent with the findings of Rooney
and colleagues, who recently identified 5 HLA class-I-
restricted epitopes from conserved regions of the hexon
protein (Leen et al., 2004b). Three of the epitopes are
located in the N-terminal half of hexon. One epitope,
restricted by HLA A1, is located in the conserved C-
terminal (a.a. 886–894) and overlaps the HLA-A2-restricted
Fig. 7. CD8+ CTL recognize an HLA-B-restricted epitope in the hexon C-
terminus. (A) CD8+ CTL from donor 3 (A2, A31; B13, B49) were incubated
overnight with the indicated predicted hexon HLA-A2-binding motif peptides (1
μg/ml) and assayed for IFN-γ expression by ELISPOT assay at 20 h B. CD8+
CTL were stimulated with H918–927 (H918) for 2 weeks and tested for
cytotoxicity by calcein release assay. Autologous EBV-transformed lympho-
blastoid cell line (LCL), HLA-A2-matched only BM16 (A2, B18), and HLA-
A2, A31-matched only donor 9 LCL (A2, A31; B8, B38) targets were tested
with and without peptide.
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data indicate that the conserved distal 100 a.a. region of
hexon is highly immunogenic.
This is the first study to document specific CD8+ CTL
responses to the capsid proteins penton and fiber in healthy
adults. In comparison to the hexon-specific response, however,
CD8+ CTL responses to penton and fiber were weaker than the
hexon-specific cytotoxicity. Additionally, responses were
detected to penton in 4 of 5 donors and against fiber in only 3
of 5 donors. These data confirm that hexon is the immunodo-
minant capsid protein CTL target.The presence of both memory hexon-specific CD4+ and
CD8+ CTL will likely be a significant obstacle to the use of Ad
vectors for prolonged gene expression or repeated administra-
tion (Yang et al., 1994). Moreover, use of Ad vectors based on
different serotypes such as Ad35, in order to avoid serotype-
specific neutralizing Abs, will not evade T cell responses to
conserved epitopes on hexon (Sakurai et al., 2003). Although
helper-dependent or “gutted” Ads do not express new Ad
proteins and are less immunogenic, these vectors are packaged
with capsid proteins, and these input capsid proteins will
initially be recognized by memory T cells, as demonstrated
above (Morsy et al., 1998; Schiedner et al., 1998).
On the other hand, these data suggest that donor lymphocytes
may be beneficial in the treatment of Ad disease in allogeneic
SCT recipients. Donor lymphocyte infusions have been shown
to be active against EBVand cytomegalovirus (CMV) disease in
SCT recipients (Papadopoulos et al., 1994; Rooney et al., 1998).
There are several case reports of treatment of SCT recipients
with Ad disease with donor lymphocyte infusions (Bordigoni et
al., 2001; Chakrabarti et al., 2000; Hromas et al., 1994). We
have also successfully treated a T-cell-depleted SCT recipient
with severe Ad hepatitis with donor lymphocyte infusions
(manuscript in preparation). However, donor lymphocyte
infusions are associated with a significant risk of graft versus
host disease (Papadopoulos et al., 1994). As an alternative,
transfer of virus-specific CD8+ CTL has been evaluated in SCT
patients with CMV infection. Responses were documented but
were transient, suggesting that CMV-specific CD4+ T cells are
needed to maintain the response (Walter et al., 1995).
Based on this study, lymphocyte populations from most
donors will contain both memory Ad hexon-specific CD4+ and
CD8+ T cells that crossreact with different Ad serotypes.
Therefore, treatment with donor lymphocyte infusions or hexon-
specific T cells may help control Ad disease in SCT recipients. It
remains unknown, however, whether or not hexon-specific T
cell responses alone are protective in vivo. In particular, CTL
targeted to early Ad proteins may play an important role in vivo
because they could eliminate cells at an earlier stage of infection,
thus preventing viral replication and spread of Ad infection. As
an example, an analysis of CMV-specific T cell responses post-
solid organ transplant revealed that protection against CMV
disease correlated with high frequency responses to immediate
early-1 protein rather than to the major virion target protein pp65
(Bunde et al., 2005). Therefore, further studies are needed to
define the T cell responses crucial for recovery from Ad disease.
Materials and methods
Study participants
Buffy coat collections were obtained from 7 healthy adults.
Two buffy coat collections were obtained from the Thomas
Jefferson University Hospital Blood Donor Center from
anonymous blood donors. The research protocol was approved
by the Thomas Jefferson University Institutional Review Board,
and written informed consent was obtained from participants.
Donors were HLA-typed (A, B, DR, DQ, and DP) as previously
Table 2
Adenovirus T cell epitopes identified in the Ad5 hexon C-terminus
a Ad5 sequence from a.a.s 892–901 is highly conserved among most serotypes.
b H910–924 epitope was previously identified and shown to be HLA-DP4-restricted.
320 J. Tang et al. / Virology 350 (2006) 312–322described (Tang et al., 2004). Since N95% of healthy adults are
seropositive for Ad, donors were not routinely screened for anti-
Ad antibodies.
Cell lines and antibodies
The human lung carcinoma cell line A549 (ATCC CCL-185)
was maintained in DMEM supplemented with 10% FBS, 2 mM
glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin (P/
S). Donor LCL were prepared from PBMC by EBV infection, as
previously described (Olive et al., 2002). The HLA homozy-
gous LCL Boleth, Mou, MGAR, and BM16 were kindly
provided by D. Eckels, Medical College of Wisconsin (Yang et
al., 1987). LCL were maintained in RPMI supplemented with
10% FCS, glutamine, and P/S. Monoclonal antibodies (mAbs)
against monomorphic determinants on HLA class I (W6/32) and
class II DR antigens (clone L243) were purchased from Leinco
Technologies, St. Louis, MO.
Viruses
Group C Ad5 and Group B Ad35 prototype strains were
originally obtained from M. Horowitz, Albert Einstein College
of Medicine (Kelly and Lewis, 1973). Ad virions were purified
from virus-infected A549 cell lysates by an affinity chroma-
tography method (Virapur, Carlsbad, CA) as per the manufac-
turer's instructions. The virion preparations were titered by a
plaque assay as previously described (Flomenberg et al., 1996).
UV-inactivated Ad antigen was prepared from crude lysates of
Ad5-infected A549 cells, as previously described (Flomenberg
et al., 1995). The vaccinia virus (Vac) recombinants Vac/Ad5
hexon and Vac/Ad5 penton base (penton) were purchased from
the Wistar Institute for Gene Therapy (Philadelphia, PA) (Jooss
et al., 1998). The Vac/Ad2 fiber recombinant was kindly
provided by J. Engler, University of Alabama, Birmingham, AL
(Hong and Engler, 1991), and a Vac/influenza M2 protein
recombinant was originally obtained from B. Moss, NIH (Smith
et al., 1987). Recombinant proteins are expressed under control
of the Vac early–late 7.5 promotor in each of these vectors. Vac
recombinants were grown and titered in 143 TK− cells, as
previously described (Olive et al., 2002). Expression of each Ad
protein from the Vac recombinants was confirmed by Western
blot analysis of infected cell lysates, using a rabbit anti-hexon
(obtained from M. Horwitz, Albert Einstein College of
Medicine) and mAbs specific for penton and fiber (obtained
from J. Engler, University of Alabama).Generation of recombinant vaccinia viruses containing hexon
truncations
The 951 a.a. Ad5 hexon ORF was amplified from viral
DNA by PCR using primers containing SalI and NotI restriction
sites—GGGGTCGACAAGATGGCTACCCCTTCGATG (for-
ward) and AAAAGCGGCCGCTTATGTTSTGGCGTTGC-
CGG (reverse). The purified hexon ORF was cloned into the
TA/TOPO cloning vector (Invitrogen, CA) and sequenced. Stop
codons were inserted at a.a. positions 437, 639, and 859 by site-
directed mutagenesis (QuickChange XL Site-Directed Muta-
genesis kit, Stratagene, CA), and mutations were verified by
DNA sequencing. Each hexon mutant ORF was then inserted
into the SalI and NotI restriction sites of the Vac expression
vector pSCII under the control of the Vac 7.5 promoter
(Chakrabarti et al., 1985). Vac/Ad recombinants were prepared
by homologous recombination of vector DNA with the
Copenhagen Vac strain and selection on TK− cells, as
previously described (Wysocka et al., 1994).
Western blot assay
Expression of each Vac/mutant hexon recombinant was
analyzed by Western blot analysis. A549 cells were infected
with each Vac recombinant and a control Vac at an MOI of 4 for
48 h. Aliquots of each cell lysate were run on a 10% SDS-
polyacrylamide gel and transferred to a polyvinylidene fluoride
membrane (Immobilon-P, Millipore, Bedford, MA). Mem-
branes were incubated with rabbit anti-hexon or human sera
(1:1000 dilution) followed by horseradish-peroxidase-conju-
gated anti-rabbit or anti-human IgG (1:10,000) (Santa Cruz
BioTechnology, Santa Cruz, CA). Blots were developed using a
chemiluminescence method (ECL Western blotting detection
reagents, Amersham Biosciences, Piscataway, NJ).
Synthetic peptides
HLA-A2-binding motif 9- and 10-mer peptides were
identified from the Ad5 hexon sequence using the NIH website
http://thr.cit.nih.gov/molbio/hla_bind (Parker et al., 1994).
Crude peptides were synthesized by Research Genetics
(Huntsville, AL) or Sigma-Genosys (The Woodlands, Texas).
Stock solutions (10 mM in DMSO) of each peptide were stored
in small aliquots at −80 °C.
Ex vivo ELISPOT assay. The IFN-γ ELISPOT assay
was performed, as previously described, using 96-well
321J. Tang et al. / Virology 350 (2006) 312–322polyvinylidene difluoride backed plates (Millipore, Bedford,
MA) with anti-IFN-γ mAbs purchased from Mabtech (Stock-
holm, Sweden) (Olive et al., 2001). Cells were incubated with
antigen, peptide, or targets (Ad-infected or uninfected DC at an
effector/target ratio of 30:1) in 100 μl RPMI supplemented with
10% pooled human AB sera (Atlanta Biologicals, Atlanta, GA),
10 mM HEPES, glutamine, and P/S (T cell media) in duplicate
wells for 20 h. Spot-forming cells (SFCs) were detected with a
biotin–avidin alkaline phosphatase conjugate. Data were
analyzed using a paired t test to compare the mean number of
spots in the duplicate control and experimental microwells.
Preparation of dendritic cells
CD14+ cells were isolated from PBMC by positive
immunomagnetic separation using CD14 Microbeads (Miltenyi
Biotec, CA) per the manufacturer's directions. CD14+ cells
(4 × 105/ml) were placed in a 6-well plate in RPMI 1640
supplemented with 1% human AB sera, HEPES, glutamine, and
P/S (DC media) containing GM-CSF (800 U/ml) (Berlex,
Wayne, NJ) and IL-4 (1000 U/ml) (BD Pharmingen, San Diego,
CA). Fresh cytokines were added on day 3. Non-adherent cells
(immature DC) were harvested on day 5. 1 × 106 DC were
infected with Ad 200 pfu/cell in 200 μl media for 1.5 h or left
untreated. DC were re-plated in 6-well plates, and maturation
was induced by the addition of 10 ng/ml IL-1β (BD
Pharmingen, San Diego, CA), 1000 U/ml IL-6, 10 ng/ml
tumor necrosis factor-α (TNF-α), and 1 μg/ml prostaglandin E2
(PGE2) (Sigma, St. Louis, MO) for 48 h.
Isolation of CD8+-enriched T cells
Isolation of purified CD8+ T cells was performed by
immunomagnetic depletion of non-CD8+ T cells with the
Miltenyi CD8 depletion kit (Miltenyi Biotec, CA), as per the
manufacturer's instructions. Alternatively, in some experi-
ments, PBMC were CD4+ T-cell-depleted. PBMC were
suspended at 107 cells/ml in PBS containing 2% FBS, and
2 × 107 Dynabeads M-450 coated with anti-CD4 mAb (Dynal,
Lake Success, NY) were added. After incubation for 30 min at
4–8 °C with continuous mixing, the tube was placed in a
magnetic stand, and cells remaining in solution were harvested
and washed before use. The efficiency of the depletion or
purification was confirmed to be N98% by flow cytometry.
Generation of Ad-specific T cell lines
For preparation of bulk Ad-specific CTL, 3 × 106 purified
CD8+ T cells were suspended in T cell media in 24-well plates.
DC were infected overnight with Ad5 200 pfu/cell and added at
a T cell:DC ratio of 10:1 to 30:1. At day 7, cells were re-
stimulated with Ad-infected DC (irradiated with 3000 rad). For
preparation of peptide-specific T cell lines (TCL), 3 × 106
PBMC were incubated with 10 μM/ml of each peptide, and IL-2
5 U/ml was added on day 5. Cells were re-stimulated with
peptide-loaded irradiated PBMC at day 7. IL-2 5 U/ml was
added to each TCL on days 9 and 11, and lines were assayed forcytotoxicity around day 14. In some experiments, cell lines
were re-stimulated on day 14.
Cytotoxic T cell assay
Cytotoxicity was measured by a calcein release assay as
previously described (Olive et al., 2002). LCL targets were
infected overnight with each recombinant Vac at 10 pfu/ml
or mock-infected as a control. In brief, targets were labeled
with 5 μg/ml calcein (Molecular Probes, Eugene, OR) for 30
min at 37 °C, washed extensively, and incubated with
effectors in microtiter wells for 3 h. Assays were performed
in triplicate using a range of effector/target ratios. Cells were
pelleted, 100 μl of each supernatant transferred to new wells,
and fluorescence was measured on a Victor2 1420 multilabel
counter (Wallace, Gaithersburg, MD). Spontaneous release
(SR) was measured from target cells incubated in medium
alone. Maximal release (MR) was measured from target
cells incubated with 0.1% Triton in 50 mM sodium borate,
pH 9.0. Percent lysis is calculated as follows: [(sample
fluorescence − SR fluorescence) / (MR fluorescence − SR
fluorescence)] × 100.
Cytokine flow cytometry assay (CFC)
The CFC assay was performed using the Fast Immune CD8
intracellular Cytokine Detection kit (BD Sciences, CA), as
previously described (Tang et al., 2005). Briefly, PBMC (0.5–
1 × 106) were incubated with either Ad5-infected or uninfected
autologous DC at a PBMC:DC ratio of 30:1 for a total of 6 h and
stained with the mAbs anti-Hu-IFN-γ FITC, CD69 PE, CD8
PerCP-CY5.5, and CD3 APC. An aliquot of each sample was
also stained with γ2α FITC, γ1 PE, CD8 PerCP-Cy5.5, and
CD3 APC mAbs as an isotype control. Samples were collected
on a FACSCalibur flow cytometer (BD, San Jose, CA), and
analysis was performed using CellQuest software.
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